Last reviewed · How we verify
Pertuzumab + trastuzumab
Pertuzumab and trastuzumab are monoclonal antibodies that block HER2 signaling by binding to different epitopes on the HER2 receptor, preventing ligand-induced dimerization and receptor activation.
Pertuzumab and trastuzumab are monoclonal antibodies that block HER2 signaling by binding to different epitopes on the HER2 receptor, preventing ligand-induced dimerization and receptor activation. Used for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (neoadjuvant and adjuvant settings).
At a glance
| Generic name | Pertuzumab + trastuzumab |
|---|---|
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Drug class | HER2-targeted monoclonal antibody combination |
| Target | HER2 (human epidermal growth factor receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Trastuzumab binds to domain IV of HER2 and blocks HER2/HER3 dimerization, while pertuzumab binds to domain II and prevents HER2 heterodimerization with other HER family members. Together, they provide complementary mechanisms of HER2 inhibition, leading to enhanced antibody-dependent cellular cytotoxicity and reduced proliferation in HER2-positive tumors.
Approved indications
- HER2-positive metastatic breast cancer
- HER2-positive early-stage breast cancer (neoadjuvant and adjuvant settings)
Common side effects
- Cardiotoxicity / left ventricular dysfunction
- Infusion reactions
- Diarrhea
- Nausea
- Fatigue
- Neutropenia
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management (PHASE2)
- A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo®. (PHASE1)
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (PHASE3)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: